# 1 What does the COVID-19 pandemic mean for the next

# 2 decade of onchocerciasis control and elimination?

- 3
- 4 Original article
- 5

6 Jonathan I.D. Hamley<sup>a,b\*</sup>, David J. Blok<sup>c</sup>, Martin Walker<sup>a,d</sup>, Philip Milton<sup>a,b</sup>,

7 Adrian D. Hopkins<sup>e</sup>, Louise C. Hamill<sup>f</sup>, Philip Downs<sup>f</sup>, Sake J. de Vlas<sup>c</sup>, Wilma A. Stolk<sup>c</sup>,

8 Maria-Gloria Basáñez<sup>a,b</sup>

<sup>a</sup> London Centre for Neglected Tropical Disease Research (LCNTDR), Department of

10 Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St Mary's

11 campus), Imperial College London, Norfolk Place, London W2 1PG, UK; <sup>b</sup> MRC Centre for

12 Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School

13 of Public Health, Faculty of Medicine (St Mary's campus), Imperial College London, Norfolk

14 Place, London W2 1PG, UK; <sup>c</sup> Department of Public Health, Erasmus MC, University Medical

- 15 Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands; <sup>d</sup> London Centre
- 16 for Neglected Tropical Disease Research (LCNTDR), Department of Pathobiology and
- 17 Population Sciences, Royal Veterinary College, University of London, Hatfield AL9 7TA, UK;
- <sup>e</sup>Neglected and Disabling Diseases of Poverty Consultant, Kent, UK; <sup>f</sup>Sightsavers, 35
- 19 Perrymount Road, Haywards Heath, RH16 3BW, UK

20 <sup>\*</sup>corresponding author; E-mail: jonathan.hamley11@imperial.ac.uk

21 **Data availability statement:** No new data were used in this study. The model code is

22 available on Github.

## 23 Abstract

24 **Background** Mass drug administration (MDA) of ivermectin for onchocerciasis has been

- 25 disrupted by the SARS-CoV-2 (COVID-19) pandemic. Mathematical modelling can help
- 26 predict how missed/delayed MDA will affect short-term epidemiological trends and
- 27 elimination prospects by 2030.
- 28 **Methods** Two onchocerciasis transmission models (EPIONCHO-IBM and ONCHOSIM) are
- 29 used to simulate microfilarial prevalence trends, elimination probabilities, and age-profiles
- 30 of Onchocerca volvulus microfilarial prevalence and intensity, for different treatment
- 31 histories and transmission settings, assuming no interruption, a 1-year (2020) or 2-year
- 32 (2020–2021) interruption. Biannual MDA or increased coverage upon MDA resumption are
- 33 investigated as remedial strategies.
- 34 **Results** Programmes with shorter MDA histories and settings with high pre-intervention
- 35 endemicity will be the most affected. Biannual MDA is more effective than increasing
- 36 coverage for mitigating COVID-19's impact on MDA. Programmes which had already
- 37 switched to biannual MDA should be minimally affected. In high transmission settings with
- 38 short treatment history, a 2-year interruption could lead to increased microfilarial load in
- 39 children (EPIONCHO-IBM) or adults (ONCHOSIM).
- 40 **Conclusions** Programmes with shorter (annual MDA) treatment histories should be
- 41 prioritised for remedial biannual MDA. Increases in microfilarial load could have short- and
- 42 long-term morbidity and mortality repercussions. These results can guide decision-making
- 43 to mitigate the impact of COVID-19 on onchocerciasis elimination.
- 44
- 45 Key Words: COVID-19, Ivermectin, Mass Drug Administration, Mathematical Modelling,
- 46 Onchocerciasis, Remedial Strategies
- 47
- 48 **Running Title:** COVID-19 and onchocerciasis elimination

- 50
- 51
- 52

# 53 Introduction

54	The SARS-CoV-2 virus (COVID-19) pandemic has led to severe disruptions to routine public
55	health services on a global scale. These disruptions are expected to be particularly
56	pronounced in low- and middle-income countries due to already under-resourced
57	healthcare systems. On April $1^{st}$ 2020, the World Health Organization (WHO) advised that
58	mass drug administration (MDA) and epidemiological surveys for neglected tropical diseases
59	(NTDs) tackled by preventive chemotherapy and transmission control (PCT) should be
60	postponed. <sup>1</sup> Updated guidance was released on July 27 <sup>th</sup> , which included a decision-making
61	framework, allowing countries to restart routine MDA given careful risk assessment. <sup>2</sup>
62	Onchocerciasis is one such PCT disease, centred on ivermectin (Mectizan $^{ m \$}$ ) MDA, delivered
63	annually in the majority of endemic countries in Africa.
64	
65	Although so-called 'lockdowns' and delayed MDA might be effective in temporally reducing
66	the transmission of the SARS-CoV-2 virus, the implications for both short- and long-term
67	
60	onchocerciasis transmission are less clear. The impact of the Ebola outbreaks in West Africa
68	onchocerciasis transmission are less clear. The impact of the Ebola outbreaks in West Africa (2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide
68 69	
	(2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide
69	(2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide some insight into the implications of withdrawing routine public health services. <sup>3,4</sup> However,
69 70	(2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide some insight into the implications of withdrawing routine public health services. <sup>3,4</sup> However, comparability is limited due to the stark differences in the scale and manifestations of Ebola
69 70 71	(2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide some insight into the implications of withdrawing routine public health services. <sup>3,4</sup> However, comparability is limited due to the stark differences in the scale and manifestations of Ebola and COVID-19. There are concerns that delaying MDA might increase onchocerciasis
69 70 71 72	(2013–2016) on morbidity due to other diseases (such as tuberculosis and HIV) can provide some insight into the implications of withdrawing routine public health services. <sup>3,4</sup> However, comparability is limited due to the stark differences in the scale and manifestations of Ebola and COVID-19. There are concerns that delaying MDA might increase onchocerciasis morbidity in the short term, and in the long term, undermine progress made towards the

76 MDA for onchocerciasis will be most pronounced and to identify the most effective 77 mitigation strategies to help affected programmes to get back on track. This will allow 78 better planning and prioritisation of ivermectin distribution/treatment upon safe MDA 79 resumption. 80 81 Delayed ivermectin MDA, or reduced treatment coverage, could result not only from 82 population-wide lockdowns to reduce COVID-19 transmission and the resulting redirection 83 or disruption of health services, but also from shortages in drug availability (due to slower 84 production and supply chains, or exceeded drug shelf-life by the time MDA recommences).<sup>6,7</sup> Deadlines for drug orders (typically by August for delivery in the following 85 86 year), as required by the Mectizan Donation Program (MDP, the body providing oversight 87 for ivermectin donation to endemic countries), might also be problematic. In addition to 88 these challenges, programmes will have to be adaptive in the face of unforeseen setbacks which may emerge as MDA recommences, remedial strategies (such as increased MDA 89 90 coverage and/or frequency) are attempted, and as the COVID-19 pandemic progresses. 91 92 Mathematical models of onchocerciasis transmission provide a useful predictive tool for 93 understanding the impacts of ivermectin MDA interruptions on the short-term (increases in 94 transmission intensity) and long-term (elimination prospects), as well as the potential 95 benefit of remedial mitigation strategies to help programmes get back on track. Although 96 the resurgence of helminth transmission is typically slower than that of viral, bacterial, and 97 protozoan infections (due to differences in life-history), short-term increases in infection prevalence and intensity may increase onchocerciasis-associated morbidity.<sup>8</sup> Delays in 98 99 treating children who would otherwise receive ivermectin when turning 5 could result in

100 higher microfilarial loads experienced early in life, which may impact health outcomes in

101 later years.<sup>9</sup>

102

103	In this paper, we use the EPIONCHO-IBM and ONCHOSIM transmission models to: i) quantify
104	where (in terms of transmission setting and treatment history) the impact of interruptions
105	to ivermectin MDA for onchocerciasis will be most pronounced, allowing better planning
106	and prioritisation of ivermectin distribution/treatment upon resumption, and ii) investigate
107	how mitigation strategies based on increased frequency (biannual MDA) of increased
108	coverage can help affected programmes to get back on track. Both models contributed
109	insights to inform the WHO 2021–2030 NTD Roadmap, <sup>10</sup> and provided preliminary but less
110	comprehensive results for a report to the WHO on the impact of COVID-19 on NTD
111	programmes. <sup>11</sup>

112

## 113 Materials and Methods

### 114 *Models*

We used two individual-based stochastic transmission models, namely EPIONCHO-IBM<sup>12</sup> 115 and ONCHOSIM<sup>13</sup> to address seven questions concerning the effect of MDA disruptions due 116 117 to COVID-19: (i) what is the impact of delaying treatment for one or two years upon 118 microfilarial prevalence trends and probability of elimination by 2030?; (ii) which pre-119 intervention endemicity levels are particularly vulnerable?; (iii) how much more vulnerable 120 are programmes with shorter treatment histories than those with longer ones?; (iv) which 121 age groups will be most affected?; (v) are remedial strategies based on increasing treatment 122 frequency (to biannual MDA) or increasing treatment coverage during the early stages of

MDA resumption useful for mitigating any setbacks?; (vi) how will programmes that had
already switched to biannual MDA be impacted?; and (vii) what will be the effect on (West
African) countries whose NTD programmes had already been disrupted by the Ebola
outbreak in 2014?
In the context of a 1-year interruption or 1 year of missed MDA, the terms 'interruption' or

129 'missed' are used to describe a situation in which the MDA round planned to take place 12 130 months after a successful round pre-COVID19 is not delivered (regardless of the calendar 131 month in which treatment is usually distributed according to setting). 'Remedial' MDA implies that once MDA can safely resume,<sup>2</sup> additional MDA (either an extra round or 132 133 increased coverage within one round) is delivered. Hence, 'remedial' biannual MDA can be 134 interpreted as 'delayed treatment' if a round of annual MDA is not delivered when planned 135 but given in addition to the planned round in the following (not necessarily calendar) year. 136 Although, for simplicity, modelling results are presented as if MDA were delivered at the 137 beginning of each year, what is important is the duration between two consecutive MDA 138 rounds, and whether MDA is delivered with increased frequency or coverage when 139 treatment can recommence. 140

Supplementary Information A: Supplementary Methods provides a detailed description of the models. All (therapeutic) coverage levels refer to the percentage of people treated out of the total population, where total population includes children <5 years old and individuals who never take treatment (non-participation). Fig. S1 illustrates how elimination probabilities are calculated.

146

- 147 We followed the five principles of the Neglected Tropical Disease Modelling Consortium,<sup>14</sup>
- 148 to advocate and adhere to using good practice for policy-relevant modelling. Supplementary
- 149 Table S1 presents the PRIME-NTD (Policy-Relevant Items for Reporting Models in
- 150 Epidemiology of Neglected Tropical Diseases) table.
- 151
- 152 Scenarios
- 153 Treatment histories and transmission settings
- 154 We simulated a range of scenarios reflecting pre-control endemicity and historical
- 155 treatment durations in the former Onchocerciasis Control Programme in West Africa (OCP,
- 156 1975–2002), specifically areas in the western extension in which ivermectin MDA was
- 157 implemented without vector control,<sup>15</sup> and the African Programme for Onchocerciasis
- 158 Control (APOC, 1995–2015).<sup>16</sup>
- 159
- 160 **Pre-control endemicity:** For the sake of completeness, we considered pre-intervention
- 161 onchocerciasis endemicity levels given by baseline *Onchocerca volvulus* microfilarial
- 162 prevalence of 20–85% (i.e. from hypoendemic to highly hyperendemic settings), although
- 163 APOC prioritised treatment only in areas with microfilarial prevalence  $\geq$ 40%.
- 164
- 165 History of ivermectin MDA: Annual ivermectin MDA programmes were simulated with start
- 166 years 2000, 2003, 2006, 2009, 2012, 2014, 2017 and 2020, assuming that 65% of the total
- 167 population is treated per round (i.e. approximately 80% coverage of eligible individuals aged
- $168 \ge 5$  years). The level of systematic non-participation was assumed to be 5%.
- 169

170	Pre-existing biannual MDA programmes: We also modelled scenarios for pre-existing
171	biannual programmes preceded by low coverage annual MDA motivated by the situation in
172	the Madi-Mid North focus in Uganda, <sup>17</sup> where the main vector is <i>Simulium damnosum sensu</i>
173	stricto (for which both models are parameterised). These pre-existing biannual programmes
174	were assumed to have started in 1994 with annual MDA at 25% coverage (due for instance,
175	to internal conflict, as was the case of the Madi-Mid North focus) until 2012, when biannual
176	treatment with 75% coverage of the total population (approximately 90% coverage of
177	eligible individuals) began. <sup>17</sup> A pre-intervention 50% microfilarial prevalence was motivated
178	by the baseline values for Adjumani-Moyo, <sup>16</sup> and Kitgum <sup>18</sup> in the Madi-Mid North focus.
179	
180	Previous Ebola (2013–2014) outbreak: We modelled settings previously affected by the
181	Ebola outbreak in western Africa in 2014, which were broadly motivated by the treatment
182	histories in Sierra Leone, Liberia and Guinea. <sup>19–21</sup> We assumed annual treatment from 2003
183	to 2013 (with coverage gradually increasing from 25% in 2003 to 65% in 2013), no treatment
184	in 2014, 30% coverage in 2015, 65% coverage in 2016–2019, no treatment in 2020, 50%
185	coverage in 2021, and 65% coverage from 2022–2030.
186	

187 Modelling interruptions due to COVID-19

We projected microfilarial dynamics and estimated elimination probabilities assuming either a 1-year (2020) or 2-year (2020 and 2021) interruption to ivermectin MDA. Additionally, we tested various assumptions of delays in achieving pre-COVID-19 coverage upon treatment resumption, e.g. missing MDA in 2020 but gradually increasing coverage from 30% in 2021, to 50% in 2022, and to 65% in 2023–2030. Levels of systematic non-participation were set at 5%.

194

#### 195 Modelling remedial strategies

196	We modelled the effectiveness of increasing frequency (to biannual treatment at 65%
197	coverage) or therapeutic coverage (to 75% for annual treatment) as strategies for mitigating
198	the impact of missed treatment rounds (either in 2020 or in 2020 and 2021). For a selection
199	of the scenarios described above, we investigated the capacity for remedial treatment to
200	revert the microfilaridermia trends and restore elimination probabilities (with MDA ceasing
201	in 2030) to those predicted without interruption. Typically, MDP only approves ivermectin
202	donations for biannual treatment if programmes can demonstrate sufficiently high coverage
203	in preceding years. Therefore, we assumed that remedial biannual MDA followed only after
204	a year of annual 65% coverage once programmes restart.
204 205	a year of annual 65% coverage once programmes restart.
	a year of annual 65% coverage once programmes restart. <b>Outcome measures:</b> We present three model outputs to understand the implications of
205	
205 206	<b>Outcome measures:</b> We present three model outputs to understand the implications of
205 206 207	<b>Outcome measures:</b> We present three model outputs to understand the implications of interruptions to MDA: (i) temporal trends in microfilarial prevalence (percent) to
205 206 207 208	Outcome measures: We present three model outputs to understand the implications of interruptions to MDA: (i) temporal trends in microfilarial prevalence (percent) to understand the short-term implications; (ii) probabilities of achieving elimination by 2030 to

## 212 **Results**

### 213 Impact of interruptions to ivermectin MDA for annual programmes

214 **Temporal microfilarial prevalence trends:** Fig. 1 shows, for EPIONCHO-IBM and ONCHOSIM,

- the microfilarial prevalence dynamics for programmes with a long (starting in 2000) and
- short (starting in 2017) history of ivermectin MDA, comparing no interruption with no

217	treatment during 2020 (and a 30% coverage at resumption in 2021) and with no treatment
218	during 2020 and 2021 (with a 30% coverage at resumption in 2022). The models
219	qualitatively agree on how the temporal microfilarial prevalence trends during an
220	interruption differ from those for continuous MDA through 2020–2021 for MDA starting in
221	2017. Increases in microfilarial prevalence after a 2-year interruption (2020–2021) are more
222	pronounced than after a 1-year (2020) interruption. How coverage, once treatment
223	recommences, influences the temporal dynamics of microfilarial prevalence after a 1-year
224	interruption is shown in Supplementary Information B: Supplementary Results, Fig. S2
225	(EPIONCHO-IBM), and Fig. S3 (ONCHOSIM). A detailed discussion of how the dynamics
226	following an interruption differ from those from without an interruption is presented in
227	Supplementary Fig. S4.
228	
229	[Figure 1 approximately here]
230	
231	Elimination probabilities: Although EPIONCHO-IBM generally predicts lower elimination
232	probabilities than ONCHOSIM, the models agree qualitatively on the impact of MDA
233	interruptions due to COVID-19. Both models predict that interruptions to MDA will reduce
234	the prospects of onchocerciasis elimination by 2030 if no mitigation strategies were
235	implemented. Both models also predict that programmes with shorter treatment histories
236	will be more vulnerable to MDA disruptions, than those which have distributed MDA for
237	longer, particularly if treatment is delayed for two years (Fig. 2). The impact of a 1- and 2-
238	year interruption on elimination probabilities with start years ranging from 2000 to 2020 is

238 year interruption on elimination probabilities with start years ranging from 2000 to 2020 is

239 presented in Supplementary Fig. S5 and S6.

240

а

#### 241 [Figure 2 approximately here]

242

#### 243 Mitigation strategies for annual programmes

244	Temporal microfilarial	prevalence trends:	Both models suggest	that for a programme with

- a short treatment history, increasing treatment frequency, i.e. implementing remedial
- biannual MDA at 65% coverage upon resumption of MDA, will be more effective at reducing
- 247 the impact of treatment disruptions than increasing treatment coverage (i.e. implementing
- remedial 75% coverage of annual MDA). We illustrate these results after a 2-year
- interruption (2020–2021) when MDA initially resumes at low annual coverage (30%, 2022),
- returns to annual 65% coverage (2023), and then either increases to a 6-monthly frequency
- for two consecutive years (2024–2025) at 65% coverage (Fig. 3), or increases to 75% annual
- 252 MDA coverage also for two consecutive years (2024–2025) (Fig. 4). Remedial biannual
- treatment results in lower microfilarial prevalence leading up to 2030 (Fig. 4) than remedial
- increased coverage (Fig. 3). The temporal microfilarial prevalence dynamics for a 1-year
- 255 interruption with either remedial increased treatment frequency or coverage are shown in

256 Supplementary Fig. S7 and S8.

257

#### 258 [Figure 3 and Figure 4 approximately here]

259

260 Elimination probabilities with remedial strategies: For a 2-year interruption, although

- 261 neither remedial strategy is sufficient to achieve the same elimination probabilities found in
- the absence of an interruption, 2 years of remedial biannual MDA results in higher
- 263 elimination probabilities than remedial increase in coverage (Supplementary Fig. S9). For
- some treatment histories and pre-intervention endemicities (which do not result in 100%

265	elimination pro	bability without i	nterruption), a :	1-year of missed	MDA followed by 1 yea	ar of
-----	-----------------	--------------------	-------------------	------------------	-----------------------	-------

- 266 remedial biannual MDA gives similar elimination probabilities to those in the absence of
- 267 MDA disruptions (Supplementary Fig. S10).
- 268

#### 269 **Pre-existing biannual programmes and those previously affected by Ebola**

- 270 For the pre-existing biannual scenarios explored (which had achieved high pre-COVID-19
- therapeutic coverage), a 1-year interruption did not result in pronounced microfilarial
- resurgence according to either model (Fig. 5). For this scenario, it was considered that
- 273 programmes would resume treatment in 2021 given their strong performance before
- 274 COVID-19, so a 2-year interruption was not investigated.
- 275

#### 276 [Figure 5 approximately here]

277

278	EPIONCHO-IBM p	redicts that the ir	npact of a 1	-year interruption	due to COVID-19 in 2020

279 on microfilarial prevalence dynamics in West African programmes that were affected by the

- 280 Ebola outbreak in 2014 will depend (like in other scenarios) on transmission setting (Fig. 6).
- 281 When assuming a 50% baseline microfilarial prevalence, there were small differences
- between no interruption and a 1-year interruption by 2030; however, for the 70% baseline
- 283 microfilarial prevalence settings, clear differences between no interruption and a 1-year
- interruption were still evident by 2030 according to both models.

285

286 [Figure 6 approximately here]

### 288 Age profiles of microfilarial prevalence and intensity

289	EPIONCHO-IBM and ONCHOSIM predict noticeably different age (and sex) patterns of
290	microfilarial prevalence and intensity after three rounds of annual ivermectin MDA, with or
291	without a 2-year (2020–2021) interruption (with MDA starting in 2017 and initial
292	microfilarial prevalence of 70%) (Fig. 7). EPIONCHO-IBM predicts higher prevalence and
293	intensity in children under the age of ten years following a 2-year MDA interruption than
294	when there is no MDA interruption, and this is particularly pronounced in boys (Fig. 7A and
295	7B for prevalence; 7E and 7F for intensity). Following the interruption, ONCHOSIM predicts
296	very low infection prevalence and intensity in children under 5 years, and an evident, but
297	smaller increase in 5–10-year olds than in EPIONCHO-IBM (Fig. 7C and 7D for prevalence; 7G
298	and 7H for intensity). By contrast, ONCHOSIM predicts a marked microfilarial prevalence
299	and intensity increase in the $\geq$ 20 years olds compared to EPIONCHO-IBM. (The baseline
300	profiles are shown as insets in Fig. 7; individual-level microfilarial load is illustrated in
301	Supplementary Fig. S11.)
302	
303	[Figure 7 approximately here]
304	

## 305 **Discussion**

306 While in the grip of the COVID-19 pandemic in April 2020, the WHO recommended to 307 suspend all epidemiological surveys and MDA activities for NTDs to help curtail the 308 transmission and spread of the SARS-CoV-2 virus.<sup>1</sup> These disruptions to ivermectin MDA 309 created concern in the NTD community regarding potential short-term increases in 310 transmission and impacts on longer-term elimination prospects for onchocerciasis,

311	particularly in the context of the EOT goals proposed by the WHO in its 2021–2030 NTD
312	roadmap. <sup>5</sup> In response to these concerns, we have used two stochastic onchocerciasis
313	transmission models, EPIONCHO-IBM and ONCHOSIM, to investigate the impact of (1- and
314	2-year) interruptions to MDA in a variety of settings motivated by the epidemiological
315	situation in endemic areas in Africa.
316	
317	Generally, the models suggest that programmes with short treatment histories of pre-
318	existing annual MDA (late-start programmes) will be the most vulnerable to a two-year
319	(2020–2021) interruption. Programmes with longer treatment histories (early-start
320	programmes) could also be adversely affected if initial endemicity levels indicate intense
321	(hyperendemic) transmission. The influence of baseline microfilarial prevalence was more
322	pronounced in EPIONCHO-IBM for both early- and late-start MDA programmes than in
323	ONCHOSIM. Although for late-start programmes a 1-year interruption to MDA impacted the
324	elimination probabilities and microfilarial prevalence in 2030, the effect would be more
325	tolerable than for a 2-year interruption; early-start programmes with lower pre-intervention
326	endemicities were mostly unaffected.
327	
328	In July 2020, the WHO issued guidelines for the resumption of MDA provided it can be
329	delivered 'safely' following a case-by-case risk-benefit assessment, with due consideration
330	of a health system's capacity to conduct such modified activities effectively in the context of
331	the ongoing COVID-19 pandemic. <sup>2</sup> Therefore, the implementation of mitigation strategies in

- the models allowed for a gradual scaling-up of therapeutic coverage once MDA resumes.
- Both models predict that remedial biannual MDA (in 2024 and 2025, after having
- demonstrated up-scaling to 65% coverage through 2022 and 2023) would be more effective

- 335 at controlling increases in infection and decreases in elimination probabilities than remedial
- high (75%) coverage of annual MDA (also in 2024 and 2025).
- 337

338	Both models also predicted that pre-existing biannual MDA programmes—which had
339	achieved a high treatment coverage for nearly a decade (in our simulations 75% pre-COVID-
340	19 coverage from 2012 inclusive to reflect a 90% coverage of eligible population)—would
341	not be adversely affected by a 1-year interruption. This was despite assuming a slow start of
342	annual MDA at low coverage (before implementing biannual MDA) to capture initial
343	difficulties in implementing treatment. <sup>17</sup> A 1-year (rather than a 2-year) interruption was
344	explored for these settings because of their pre-COVID-19 strong programmatic
345	performance. <sup>17</sup> It was also assumed that these programmes would be able to resume
346	biannual MDA at the same high coverage they had recorded before the pandemic given
347	their existing structure and commitment to achieve EOT.
348	
348 349	Some West African countries (e.g. Guinea, Liberia, Sierra Leone) had already had their
	Some West African countries (e.g. Guinea, Liberia, Sierra Leone) had already had their ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore
349	
349 350	ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore
349 350 351	ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore considered this situation, in addition to a 1-year COVID-19 interruption in 2020. Both
<ul><li>349</li><li>350</li><li>351</li><li>352</li></ul>	ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore considered this situation, in addition to a 1-year COVID-19 interruption in 2020. Both models predicted that in mesoendemic settings (50% baseline microfilarial prevalence),
<ul> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> </ul>	ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore considered this situation, in addition to a 1-year COVID-19 interruption in 2020. Both models predicted that in mesoendemic settings (50% baseline microfilarial prevalence), these two separate 1-year interruptions would not greatly impact on programmes'
<ul> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> <li>354</li> </ul>	ivermectin MDA programmes interrupted in 2014 due to the Ebola epidemic. We therefore considered this situation, in addition to a 1-year COVID-19 interruption in 2020. Both models predicted that in mesoendemic settings (50% baseline microfilarial prevalence), these two separate 1-year interruptions would not greatly impact on programmes' performance, provided that coverage levels can catch up reasonably quickly following

358

359	Although programmes measure progress in terms of reducing mean infection prevalence
360	and intensity at population level, favourable infection trends may mask heterogeneities
361	among different population sub-groups. In areas of intense transmission and only recent
362	MDA implementation, which could be exemplified by the situation of the Maridi Dam in
363	South Sudan, <sup>22</sup> children may reach their fifth birthday (when they become eligible for
364	ivermectin treatment) with a sizeable microfilarial load. This has been shown to be a
365	significant risk factor for the development of epilepsy later in life, <sup>9</sup> and could also contribute
366	to increasing the relative risk of mortality, which for a given microfilarial load is higher in
367	children than in adults. <sup>23</sup> In the Maridi villages, Ov-16 serology (a marker of exposure to
368	infection) revealed a 20% (95% CI = 13%–29%) seroprevalence in the 3–6-year-olds. <sup>22</sup>
369	Following a 2-year MDA interruption, children may not receive treatment until their 7 $^{ m th}$
370	birthday, leading to a further microfilarial load build-up. Our modelling results indicate that
371	in late-start (e.g. 2017) and high initial endemicity programmes (e.g. 70% microfilarial
372	prevalence), there might be substantial increases in infection intensity in children aged <10 $$
373	years, particularly according to EPIONCHO-IBM. In addition, both models predict that in
374	these settings, and following a 2-year MDA interruption, there will also be increases in
375	infection prevalence and intensity in older age groups (moderate in EPIONCHO-IBM but
376	pronounced in ONCHOSIM). This increase could lead to exacerbation of other
377	onchocerciasis-associated sequelae, such as troublesome itch, according to epidemiological <sup>8</sup>
378	and modelling studies linking infection and disease. <sup>24,25</sup> These results are mostly determined
379	by the assumed patterns of age- and sex-dependent exposure to infection, which differ
380	markedly between the two models. <sup>26</sup>
• • •	

381

382	Although the models agree qualitatively on the role of treatment history in the outcome of
383	interruptions to ivermectin MDA, and the differences between remedial strategies in
384	mitigating the ensuing setbacks, ONCHOSIM predicts higher elimination probabilities than
385	EPIONCHO-IBM. This is partly because EPIONCHO-IBM assumes strong regulatory processes
386	operating on parasite establishment within humans that are relaxed as transmission
387	declines during interventions, increasing the stability and resilience of the host–parasite
388	system; these processes are not assumed in ONCHOSIM. <sup>12,26,27</sup> In addition, the
389	aforementioned differences in the assumed age- and sex-specific exposure patterns, and
390	associated age and sex profiles of infection results in ONCHOSIM predicting a lower
391	microfilarial intensity in children under 5, while in EPIONCHO-IBM there exists a larger
392	reservoir of infection in untreated children, which also contributes to lower elimination
393	probabilities.
393 394	probabilities.
	probabilities. An assumption made in most of the modelled scenarios model, is that when MDA resumes
394	
394 395	An assumption made in most of the modelled scenarios model, is that when MDA resumes
394 395 396	An assumption made in most of the modelled scenarios model, is that when MDA resumes coverage will initially be lower than pre-pandemic levels and could take several years to
<ul><li>394</li><li>395</li><li>396</li><li>397</li></ul>	An assumption made in most of the modelled scenarios model, is that when MDA resumes coverage will initially be lower than pre-pandemic levels and could take several years to recover. However, the usual drug distribution modality, by which members of the
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> </ul>	An assumption made in most of the modelled scenarios model, is that when MDA resumes coverage will initially be lower than pre-pandemic levels and could take several years to recover. However, the usual drug distribution modality, by which members of the community present at a focal point to receive ivermectin, could be replaced by door-to-door
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> </ul>	An assumption made in most of the modelled scenarios model, is that when MDA resumes coverage will initially be lower than pre-pandemic levels and could take several years to recover. However, the usual drug distribution modality, by which members of the community present at a focal point to receive ivermectin, could be replaced by door-to-door drug distribution (as a result of social distancing measures). Depending on local
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> </ul>	An assumption made in most of the modelled scenarios model, is that when MDA resumes coverage will initially be lower than pre-pandemic levels and could take several years to recover. However, the usual drug distribution modality, by which members of the community present at a focal point to receive ivermectin, could be replaced by door-to-door drug distribution (as a result of social distancing measures). Depending on local circumstances, some programmes may achieve well-documented and high coverage levels,

404 remedial strategies to mitigate the impact of the current pandemic. This is because, while

405 these approaches are very promising,<sup>28–30</sup> they are currently not operationally implemented

406 by national control programmes. However, where vector control is practicable, it should be
407 considered as a complementary intervention, when it is more conducive than
408 chemotherapeutic approaches to implementation in a socially-distanced manner.<sup>2</sup>
409

410 **Conclusions and Recommendations** 

411 Both EPIONCHO-IBM and ONCHOSIM indicate that ivermectin MDA programmes with

412 shorter treatment histories will be most vulnerable to MDA interruptions caused by the

413 COVID-19 pandemic, particularly if treatment cannot be resumed safely in 2021. This impact

414 may be noticeable in local infection resurgence in higher endemicity settings and may

415 reduce the probability of achieving EOT by 2030. Programmes with longer treatment

416 histories of annual MDA that have achieved and maintained a coverage of 65% are

417 predicted to be less affected (but not totally impervious) to interruptions of ivermectin

418 MDA, particularly if high initial endemicity indicates highly propitious transmission

419 conditions. Young children have the potential to be negatively affected by increased levels

420 of transmission resulting from missed MDA rounds, particularly for a 2-year interruption in

421 highly endemic settings recently incorporated to ivermectin MDA programmes, depending

422 on local age-exposure patterns.

423

The impact of COVID-19 on progress towards the WHO 2021–2030 goals is best ameliorated by implementing biannual MDA as soon as pre-COVID-19 levels of therapeutic coverage are restored (in our simulations to 65% of the total population in 2024–2025). This mitigation strategy is indicated as more effective than increasing annual MDA coverage (to 75%).

428

429	MDA programmes should promptly conduct the risk-benefit evaluations indicated by the
430	WHO, <sup>2,31</sup> so alternative modalities of MDA delivery can be put in place safely and effectively
431	to resume MDA and regain pre-COVID-19 levels of coverage where possible (e.g. door-to-
432	door distribution with household members measuring themselves with disinfected height
433	poles and community drug distributors leaving tablets at the doorstep and observing
434	household members swallowing the tablets with safe social distancing). Additionally, in
435	August 2020, The United States Agency for International Development (USAID) released
436	guidance on how best to implement MDA in the context of COVID-19. <sup>32</sup> To complement the
437	WHO and USAID documentation, we offer a decision-making tree to summarise our results
438	and recommendations which we hope will help programme managers to navigate the
439	landscape of ivermectin MDA for onchocerciasis during the ongoing pandemic (Fig. 8).
440	
441	[Figure 8 approximately here]
442	
442 443	Abbreviations
443	Abbreviations
443 444	Abbreviations ABR = annual biting rate, APOC = African Programme for Onchocerciasis Control, EOT =
443 444 445	Abbreviations ABR = annual biting rate, APOC = African Programme for Onchocerciasis Control, EOT = elimination of transmission, IBM = individual-based model, MDA = mass drug
<ul><li>443</li><li>444</li><li>445</li><li>446</li></ul>	Abbreviations ABR = annual biting rate, APOC = African Programme for Onchocerciasis Control, EOT = elimination of transmission, IBM = individual-based model, MDA = mass drug administration, aMDA = annual mass drug administration, bMDA = biannual mass drug

450 World Health Organization.

#### 452 Authors contributions

- 453 JIDH: Conceptualization, Methodology, Investigation, Formal analysis, Software,
- 454 Visualization, Writing original draft, Writing review & editing
- 455 DJB: Conceptualization, Formal analysis, Software, Writing review & editing
- 456 MW: Conceptualization, Methodology, Supervision, Writing review & editing
- 457 PM: Methodology, Writing review & editing
- 458 ADH: Conceptualization, Writing review & editing
- 459 LCH: Conceptualization, Writing review & editing
- 460 PD: Visualization, Writing review & editing
- 461 SJdV: Funding acquisition, Supervision, Writing review & editing
- 462 WAS: Conceptualization, Supervision, Writing review & editing
- 463 MGB: Conceptualization, Methodology, Funding acquisition, Supervision, Visualization,
- 464 Writing original draft, Writing review & editing

465

#### 466 Funding

- 467 This work was supported by the Bill and Melinda Gates Foundation via the NTD Modelling
- 468 Consortium (grant number OPP1184344); the UK Medical Research Council (MRC Doctoral
- 469 Training Programme award to PM); MRC and the UK Department for International Development
- 470 (DFID) Joint Centre Funding under the MRC/DFID Concordat agreement of the European Union
- 471 and European and Developing Countries Clinical Trials Partnership 2 (grant number
- 472 MR/R015600/1 (JIDH, PM, MGB).

473

#### 474 **Conflict of interest statement**

475 The authors have no conflicts of interest to disclose.

### 476

### 477 Code availability

- 478 The code of EPIONCHO-IBM is available at <u>https://github.com/jonathanhamley/EPIONCHO-</u>
- 479 IBM. The code of ONCHOSIM is available at <u>https://gitlab.com/erasmusmc-public-</u>
- 480 health/wormsim.previous.versions/-/blob/master/wormsim-2.58Ap27.zip
- 481

### 482 Description of SI File

- 483 Detailed description of modelling methodology and additional results.
- 484

## 485 **References**

- 486 1 World Health Organization. COVID-19: WHO issues interim guidance for implementation
  487 of NTD programmes. 1 April 2020.
- 488 <u>https://www.who.int/neglected\_diseases/news/COVID19-WHO-interim-guidance-</u>
- 489 <u>implementation-NTD-programmes/en/</u> [accessed 17 October 2020].
- 490 2 World Health Organization. Considerations for implementing mass treatment, active
- 491 case-finding and population-based surveys for neglected tropical diseases in the context
- 492 of the COVID-19 pandemic. Interim guidance. 27 July 2020.
- 493 https://www.who.int/publications/i/item/WHO-2019-nCoV-neglected-tropical-diseases-
- 494 <u>2020-1</u> [accessed 17 October 2020].
- 495 3 Parpia AS, Ndeffo-Mbah ML, Wenzel NS, Galvani AP. Effects of response to 2014-2015
- 496 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, West Africa. Emerg
  497 Infect Dis 2016;22(3):433241.
- 4 Sochas L, Channon AA, Nam S. Counting indirect crisis-related deaths in the context of a
  low-resilience health system: the case of maternal and neonatal health during the Ebola
  epidemic in Sierra Leone. Health Policy Plan 2017;32(Suppl 3):iii322iiii39.
- 501 5 World Health Organization. Ending the neglect to attain the Sustainable Development
- 502 Goals A road map for neglected tropical diseases 2021–2030.
- 503 <u>https://www.who.int/neglected\_diseases/Ending-the-neglect-to-attain-the-SDGs--NTD-</u>
- 504 <u>Roadmap.pdf?ua=1</u> [accessed 18 October 2020].

- 505 6 Molyneux DH, Aboe A, Isiyaku S, Bush S. COVID-19 and neglected tropical diseases in
- 506 Africa: impacts, interactions, consequences. Int Health. 2020;12(5):367272.
- 507 7 Chaumont C, Kamara K, Baring E, et al. The SARS-CoV-2 crisis and its impact on neglected
- 508 tropical diseases: Threat or opportunity? PLoS Negl Trop Dis 2020;14(9):e0008680.
- 509 8 Brieger WR, Awedoba AK, Eneanya CI, et al. The effects of ivermectin on onchocercal
- skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 1998;
  3(12):951261.
- 512 9 Chesnais CB, Nana-Djeunga HC, Njamnshi AK, et al. The temporal relationship between
  513 onchocerciasis and epilepsy: a population-based cohort study. Lancet Infect Dis 2018;
  514 18(11):1278286.
- 515 10 NTD Modelling Consortium Onchocerciasis Group. The World Health Organization 2030
- 516 goals for onchocerciasis: Insights and perspectives from mathematical modelling. Gates517 Open Res 2019;3:1545.
- 518 11 NTD Modelling Consortium. The potential impact of programmes interruptions due to 519 COVID-19 on 7 neglected tropical diseases: a modelling-based analysis.
- 519 COVID-19 on 7 neglected tropical diseases: a modelling-based analysis.
- 520 <u>https://gatesopenresearch.org/documents/4-115</u> [accessed 18 October 2020].
- 521 12 Hamley JID, Milton P, Walker M, Basáñez MG. Modelling exposure heterogeneity and
- 522 density dependence in onchocerciasis using a novel individual-based transmission
- model, EPIONCHO-IBM: Implications for elimination and data needs. PLoS Negl Trop Dis
   2019;13(12):e0007557.
- 525 13 Coffeng LE, Stolk WA, Hoerauf A, et al. Elimination of African onchocerciasis: modeling
  526 the impact of increasing the frequency of ivermectin mass treatment. PLoS One
  527 2014;9(12):e115886.
- 528 14 Behrend MR, Basáñez MG, Hamley JID, et al. Modelling for policy: The five principles of
   529 the Neglected Tropical Diseases Modelling Consortium. PLoS Negl Trop Dis 2020;14(4):
   530 e0008033.
- 53115 Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med532Parasitol 2008;102(Suppl 1):1327.
- 533 16 Tekle AH, Zouré HG, Noma M, et al. Progress towards onchocerciasis elimination in the 534 participating countries of the African Programme for Onchocerciasis Control:
- 535 epidemiological evaluation results. Infect Dis Poverty 2016;5(1):66.

- 536 17 Katabarwa MN, Lakwo T, Habomugisha P, et al. After 70 years of fighting an age-old
- scourge, onchocerciasis in Uganda, the end is in sight. Int Health 2018;10(Suppl
- 538 1):i792i88.
- 539 18 Carter Center, Ministry of Health Uganda. Insight Special 2011. Proceedings of Uganda
- 540 Onchocerciasis Elimination Expert Advisory Committee. 4th Session, 15217 August 2011,
  541 Kampala, Uganda.
- 542 <u>https://mhjapply.cartercenter.org/resources/pdfs/news/health\_publications/river\_blind</u>
   543 ness/insight-special-newsletter-2011.pdf [accessed 18 October 2020].
- Hodges ME, Koroma JB, Sonnie M, et al. Neglected tropical disease control in post-war
  Sierra Leone using the Onchocerciasis Control Programme as a platform. Int Health
  2011;3(2):69274.
- 547 20 Thomas BC, Kollie K, Koudou B, Mackenzie C. Restarting NTD programme activities after 548 the Ebola outbreak in Liberia. Infect Dis Poverty. 2017;6(1):52.
- 549 21 Koroma JB, Sesay S, Conteh A, et al. Impact of five annual rounds of mass drug
  550 administration with ivermectin on onchocerciasis in Sierra Leone. Infect Dis Poverty
  551 2018;7(1):30.
- Lakwo TL, Raimon S, Tionga M, et al. The role of the Maridi Dam in causing an
   onchocerciasis-associated epilepsy epidemic in Maridi, South Sudan: An epidemiological,
   sociological, and entomological study. Pathogens 2020;9(4):315.
- Walker M, Little MP, Wagner KS, et al. Density-dependent mortality of the human host
  in onchocerciasis: relationships between microfilarial load and excess mortality. PLoS
  Negl Trop Dis 2012;6(3):e1578.
- 24 Coffeng LE, Stolk WA, Zouré HG, et al. African Programme for Onchocerciasis Control
  1995-2015: model-estimated health impact and cost. PLoS Negl Trop Dis 2013;7(1):
  e2032.
- 561 25 Turner HC, Walker M, Churcher TS, Basáñez MG. Modelling the impact of ivermectin on
   562 River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho
   563 projections. Parasit Vectors 2014;7:241.
- 26 Basáñez MG, Walker M, Turner HC, et al. River blindness: Mathematical models for
   control and elimination. Adv Parasitol 2016;94:247–341.
- 566 27 Hamley JID, Walker M, Coffeng LE, et al. Structural uncertainty in onchocerciasis
- 567 transmission models influences the estimation of elimination thresholds and selection of
- age groups for seromonitoring. J Infect Dis 2020;221(Suppl 5):S510–S518.

- 569 28 Milton P, Hamley JID, Walker M, Basáñez MG. Moxidectin: an oral treatment for human
- 570 onchocerciasis. Expert Rev Anti Infect Ther 2020; Jul 26:1-15 (Online ahead of print).
- 571 29 Jacob BG, Loum D, Lakwo TL, et al. Community-directed vector control to supplement
- 572 mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of
- 573 Northern Uganda. PLoS Negl Trop Dis 2018;12(8):e0006702.
- 574 30 Katabarwa MN, Habomugisha P, Khainza A, et al. Elimination of Simulium neavei-
- 575 transmitted onchocerciasis in Wambabya-Rwamarongo focus of Western Uganda. Am J
- 576 Trop Med Hyg 2020;103(3):1135–42.
- 577 31 World Health Organization. Rapid risk assessment of acute public health events. 2012.
- 578 <u>https://www.who.int/csr/resources/publications/HSE\_GAR\_ARO\_2012\_1/en/</u> [accessed
  579 18 October 2020].
- 580 32 United States Agency for International Development, Act to End NTDs East, Act to End
- 581 NTDs West. Practical approaches to implementing WHO guidance for neglected tropical
- 582 disease (NTD) programs in the context of COVID-19: Mass drug administration (MDA).
- 583 2020. <u>https://www.ntdtoolbox.org/toolbox-search/practical-approaches-implementing-</u>
- 584 <u>who-guidance-neglected-tropical-disease-ntd</u> [accessed 18 October 2020].

585

## 587 Figure Legends

- 588 Figure 1. Temporal dynamics of *Onchocerca volvulus* microfilarial (Mf) prevalence
- 589 assuming a 1-year (2020) and 2-year (2020–2021) interruption to annual mass drug
- 590 administration (MDA) with ivermectin due to COVID-19 and no mitigation strategies,
- 591 predicted by EPIONCHO-IBM (A-D) and ONCHOSIM (E-H).
- 592 The pre-intervention (baseline) microfilarial prevalence in individuals aged  $\geq$ 5 years is 50%
- 593 (A, C, E, G), and 70% (B, D, F, H). Annual MDA occurs from 2000 to 2030 (early-start
- programmes, A, B, E, F) or from 2017 to 2030 (late-start programmes, C, D, G, H), assuming
- 595 no treatment in 2020 only (red lines), no treatment in both 2020 and 2021 (violet lines), and
- 596 no remedial strategies subsequently. The temporal microfilarial dynamics with no
- 597 interruption to MDA are shown as green lines. The therapeutic coverage (of total
- 598 population) is assumed to be 65%, with the exception of 30% in 2021 following a 1-year
- 599 interruption and 30% in 2022 following a 2-year interruption to MDA. The proportion of
- 600 systematic non-participation is set to 5% throughout all simulations.

- 602 Figure 2. Elimination probabilities versus pre-intervention (baseline) endemicity (pre-
- 603 treatment microfilarial prevalence) predicted by (A) EPIONCHO-IBM and (B) ONCHOSIM
- 604 for early-start and late-start annual mass drug administration (MDA) with ivermectin with
- and without a 2-year (2020 and 2021) MDA interruption due to COVID-19 and no
- 606 mitigation strategies. Annual MDA programmes start in 2000 (early-start, black lines) or
- 607 2017 (late-start, grey lines) and finish in 2030. Although in the African Programme for
- 608 Onchocerciasis Control MDA treatment was prioritised for areas with microfilarial
- 609 prevalence  $\geq$ 40%, the range of baseline microfilarial prevalence in individuals aged  $\geq$ 5 years

- 610 explored is 20% 85% for the sake of completeness. No interruption to MDA is represented
- 611 by solid lines; a 2-year interruption is represented by dashed lines. The therapeutic coverage
- 612 (of total population) is assumed to be 65%, with the exception of 30% in 2022. The
- 613 proportion of systematic non-participation is set to 5% throughout all simulations.
- 614 Figure 3. Temporal dynamics of *Onchocerca volvulus* microfilarial (Mf) prevalence
- 615 predicted by EPIONCHO-IBM (A C) and ONCHOSIM (D F) with a 2-year (2020 and 2021)
- 616 interruption due to COVID-19 of mass drug administration (MDA) with ivermectin (2017 –
- 617 **2030) and remedial biannual MDA.** The pre-intervention (baseline) microfilarial prevalence
- 618 (in individuals aged  $\geq$ 5 years) is: 50% (**A**, **D**), 60% (**B**, **E**), and 70% (**C**, **F**). Grey lines represent
- no interruption to MDA; black lines indicate no treatment in 2020 and 2021 but with two
- 620 years of remedial biannual MDA in 2024 and 2025. The therapeutic coverage (of total
- 621 population) is assumed to be 65%, with the exception of 30% in 2022. The proportion of
- 622 systematic non-participation is set to 5% throughout all simulations.
- 623 Figure 4. Temporal dynamics of *Onchocerca volvulus* microfilarial (Mf) prevalence
- 624 predicted by EPIONCHO-IBM (A–C) and ONCHOSIM (D–F) with a 2-year (2020 and 2021)
- 625 interruption due to COVID-19 of annual mass drug administration (MDA) with ivermectin
- 626 (2017–2030) and remedial annual high-coverage MDA. The pre-intervention (baseline)
- microfilarial prevalence (in individuals aged ≥5 years) is: 50% (A, D), 60% (B, E), and 70% (C,
- 628 F). Grey lines represent no interruption to MDA; black lines indicate no treatment in 2020
- and 2021 but with two years of remedial high-coverage MDA in 2024 and 2025. The
- 630 therapeutic coverage (of total population) is assumed to be 65%, with the exception of 30%
- 631 in 2022, 75% in 2024 and 75% in 2025. The proportion of systematic non-participation is set
- 632 to 5% throughout all simulations.

633	Figure 5. Temporal dynamics of Onchocerca volvulus microfilarial (Mf) prevalence
634	predicted by EPIONCHO-IBM (A) and ONCHOSIM (B) in programmes with pre-existing
635	biannual mass drug administration (MDA) with ivermectin and a 1-year interruption
636	(2020) due to COVID-19. Annual MDA assumes low (25%) therapeutic coverage (of total
637	population) from 1994 to 2011 and high (75%) biannual coverage (of total population) from
638	2012 to 2019 (motivated by the Madi-Mid North focus in Uganda, where the main vector is
639	Simulium damnosum sensu stricto), with a 50% pre-intervention (baseline) microfilarial
640	prevalence (in individuals aged $\geq$ 5 years). Following resumption of MDA in 2021, coverage
641	(of total population) is assumed to reach 75% (same as pre-interruption). Black lines indicate
642	individual simulations. Green lines indicate the mean of all simulations. The proportion of
643	systematic non-participation is set to 5% throughout all simulations.
644	Figure 6. Temporal dynamics of Onchocerca volvulus microfilarial (Mf) prevalence
644 645	Figure 6. Temporal dynamics of <i>Onchocerca volvulus</i> microfilarial (Mf) prevalence predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug
645	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug
645 646	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the
645 646 647	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no
645 646 647 648	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals
645 646 647 648 649	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals aged $\geq$ 5 years is 50% (A, D), 60% (B, E) and 70% (C, F). The therapeutic coverage (of total
<ul> <li>645</li> <li>646</li> <li>647</li> <li>648</li> <li>649</li> <li>650</li> </ul>	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals aged $\geq$ 5 years is 50% (A, D), 60% (B, E) and 70% (C, F). The therapeutic coverage (of total population) is assumed to be 25% in 2003 and 2004, 30% in 2005 and 2006, 50% in 2007
<ul> <li>645</li> <li>646</li> <li>647</li> <li>648</li> <li>649</li> <li>650</li> <li>651</li> </ul>	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals aged ≥5 years is 50% (A, D), 60% (B, E) and 70% (C, F). The therapeutic coverage (of total population) is assumed to be 25% in 2003 and 2004, 30% in 2005 and 2006, 50% in 2007 and 2008, 65% in 2009 and 2012, 30% in 2015 and 65% from 2016 onwards (motivated by
<ul> <li>645</li> <li>646</li> <li>647</li> <li>648</li> <li>649</li> <li>650</li> <li>651</li> <li>652</li> </ul>	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals aged ≥5 years is 50% (A, D), 60% (B, E) and 70% (C, F). The therapeutic coverage (of total population) is assumed to be 25% in 2003 and 2004, 30% in 2005 and 2006, 50% in 2007 and 2008, 65% in 2009 and 2012, 30% in 2015 and 65% from 2016 onwards (motivated by the situation in West African countries that had experienced civil conflict and were affected
<ul> <li>645</li> <li>646</li> <li>647</li> <li>648</li> <li>649</li> <li>650</li> <li>651</li> <li>652</li> <li>653</li> </ul>	predicted by EPIONCHO-IBM (A, B, C) and ONCHOSIM (D, E, F) during annual mass drug administration (MDA) with ivermectin, assuming a 1-year interruption (2014) due to the Ebola epidemic in West Africa, a 1-year interruption due to COVID-19 in 2020 and no remedial strategies. The pre-intervention (baseline) microfilarial prevalence in individuals aged ≥5 years is 50% (A, D), 60% (B, E) and 70% (C, F). The therapeutic coverage (of total population) is assumed to be 25% in 2003 and 2004, 30% in 2005 and 2006, 50% in 2007 and 2008, 65% in 2009 and 2012, 30% in 2015 and 65% from 2016 onwards (motivated by the situation in West African countries that had experienced civil conflict and were affected by the Ebola epidemic), with the exception of 2021 (50%). Black and grey lines indicate,

656	Figure 7: Age- and sex-profiles of Onchocerca volvulus microfilarial (Mf) prevalence
657	(percent, A – D) and mean intensity (mf/skin snip, E – H) predicted by EPIONCHO-IBM (A,
658	B, E, F) and ONCHOSIM (C, D, G, H) assuming no interruption to mass drug administration
659	(MDA) with ivermectin (A, C, E, G) and a 2-year interruption to MDA in 2020 and 2021 (B,
660	D, F, H) due to COVID-19. The pre-intervention (baseline) microfilarial prevalence is 70% in
661	individuals aged ≥5 years and the age-profiles for prevalence (A, C) and intensity (E, G) at
662	baseline are shown in the figure insets. Annual MDA starts in 2017 and the profiles (solid
663	lines for males and dashed lines for females) are shown for 2022 (black), 2023 (violet), 2024
664	(purple), 2025 (red) and 2026 (yellow). The therapeutic coverage (of total population) is
665	assumed to be 65%, with the exception of 30% in 2022 ( <b>B, D, F, H)</b> . The proportion of
666	systematic non-participation is set to 5% throughout all simulations.
667	Figure 8. Decision tree for implementing ivermectin MDA following a 1- or 2-year
667	rigure 8. Decision tree for implementing ivermeetin MDA following a 1- of 2-year
668	interruption to treatment programmes as a result of COVID-19. COVID-19 risk assessment
669	conducted but risk deemed too high to safely implement MDA is represented by the red
670	box, in which case MDA is postponed until subsequent risk assessments allow treatment
671	activities to recommence. COVID-19 risk assessment conducted and deemed that MDA can

673 duration of interruption, baseline prevalence, and treatment history. MDA interruption (or

resume safely is represented by the green box. MDA strategy upon resumption is based on

672

674 missed MDA) is defined as no MDA in the period specified, i.e. 1 year (≥12 months since the 675 last round of MDA) or 2 years (≥24 months since the last round of MDA). One year of missed 676 annual MDA followed by a remedial biannual round in the following year can be interpreted 677 as delayed MDA. Pre-interruption coverage assumes that before COVID-19 programmes had 678 reached the minimum effective coverage of 65% of total population and that this value will

- 679 be reached following resumption of MDA. Early MDA start = programmes starting MDA in
- 680 2000; late MDA start = programmes commencing MDA in 2017 (these start times were
- 681 selected as they are at the two extremes of the treatment durations simulated); aMDA =
- annual MDA; bMDA = biannual MDA; MDA+ = MDA implemented following World Health
- 683 Organization guidelines for minimising the risk of COVID-19 transmission.<sup>2,31</sup>







Fig. 2



















Fig. 6

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219733; this version posted October 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

С

F

2030

2027

